Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Showing latest transactions and SEC Form 4 filings for PTGX.
11 results.
| X | Filing Date | Trade Date | Ticker | Company Name | Insider Name | Title | Trade Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-17 20:29:37 | 2026-11-16 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Chief Medical Officer | S - Sale | $124.65 | -2,718 | 81,397 | -3% | -$338,799 | |
| D | 2026-10-02 16:10:06 | 2026-09-30 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Chief Financial Officer | M - OptEx | $11.86 | +117,258 | 558,894 | 0% | +$1,390,735 |
| D | 2026-10-02 16:10:06 | 2026-09-30 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Chief Financial Officer | S - Sale+OE | $141.78 | -58,629 | 558,894 | -8% | -$8,312,294 |